Canine IMHA Immunosuppressive Therapy
An interactive executive clinical summary derived from the 2019 ACVIM Consensus Guidelines. Navigate protocols, compare single vs. dual therapy, and utilize the interactive decision support tool below.
1. The Core Rules of Immunosuppression
This section establishes the foundational pharmacological agents used in IMHA treatment. It outlines the primary and secondary drug choices, providing the fundamental rules that govern all subsequent clinical decisions in this application.
Glucocorticoids (The Foundation)
Prednisone or Prednisolone are the absolute first-line foundation of therapy.
- ✓ Rapid onset of action (hours).
- ✓ Immediately down-regulates Fc-receptor expression on macrophages.
- ✓ Halts destruction of antibody-coated red blood cells in the spleen and liver.
Mycophenolate Mofetil (The Secondary)
MMF is a secondary agent that targets T and B-lymphocyte proliferation.
- ⚠ Delayed onset of action (takes several days to reach full clinical efficacy).
- ⚠ Can never be used as monotherapy to manage acute hemolytic crises.
2. Clinical Decision Support Tool
Interact with the criteria below to determine the appropriate therapy protocol based on the patient's presentation. This interactive checklist synthesizes the ACVIM conditions for Day 1 Dual Therapy, Sequential Therapy, and Rescue Therapy into a dynamic recommendation engine.
Select Presenting Clinical Signs:
High-Risk Indicators (Day 1)
Stable Presentation (Day 1)
Post-Treatment Monitoring (Days 5-7+)
Select clinical signs from the panel to generate protocol recommendations.
Prednisone + Mycophenolate
Initiate both immediately at presentation. Patient exhibits signs of severe, high-risk, or life-threatening disease.
Prednisone Alone
Highly acceptable to start with Prednisone monotherapy for stable, extravascular IMHA presentations.
Add Mycophenolate Now
Implement MMF as a secondary rescue or steroid-sparing agent.
Conflicting Presentation
You have selected both Day 1 presenting signs and Post-Treatment outcomes. Please evaluate based on the patient's current stage of treatment.
3. Pharmacological Onset Comparison
This interactive chart visualizes the critical difference in the onset of clinical efficacy between the primary and secondary agents. Understanding this timeline is crucial for managing acute hemolytic crises, demonstrating why MMF cannot be used as monotherapy initially.
4. Absolute Contraindications
This section highlights the most critical safety warning in the ACVIM guidelines regarding polypharmacy in IMHA management.
The "Three-Drug" Absolute Red Flag
Veterinarians must AVOID prescribing three or more immunosuppressive drugs concurrently.